Isatuximab plus KRd for high-risk NDMM

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Katja Weisel, University Cancer Center Hamburg, Hamburg, DE. In this podcast she discusses the quadruplet combination of isatuximab with carfilzomib, lenalidomide and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma.In this podcast, Katja Weisel describes the interim results of the phase II GMMG-CONCEPT trial including deep and durable responses, measurable residual disease negativity, remissions, and overall survival of the first 50 patients enrolled. She also discusses the trial design, including the cytogenetic features that classify patients as high risk, as well as the safety profile and dosing regimens. Hosted on Acast. See acast.com/privacy for more information.